XML 53 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Feb. 13, 2024
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
Aug. 15, 2023
USD ($)
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Stock split, conversion ratio 30      
Net income (loss)   $ (7,167,000) $ 61,319,000  
Retained earnings accumulated deficit   482,464,000 489,631,000  
Investments under equity method carrying amount   0    
Revenue recorded included in deferred revenue   $ 59,100,000    
Tax benefits recognized,likelihood upon ultimate settlement   The tax benefits recognized in the financial statements from such a position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.    
Restricted cash   $ 22,569,000 $ 0  
Warrants outstanding | shares   2,500,000    
March 2024 Public Offering        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Warrants outstanding | shares   2,500,000    
Elo | Promissory Note        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Notes received   $ 10,000,000    
Minimum | Investments under Equity Method        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Voting interests of the investee   20.00%    
Novartis        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Revenue     38.00%  
TG Therapeutics        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Revenue   12.00%    
Prevail        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Revenue   77.00% 62.00%  
Imugene        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Aggregate principal amount       $ 13,000,000
iECURE        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Investment in equity securities   $ 3,200,000 $ 3,200,000